The first generation of GLP-1 therapies exhibit reduced susceptibility to enzymatic degradation, while providing effective glucose control, improved -cell function, body weight loss and decreased systolic blood pressure in patients with T2D (Meier, 2012) The newly developed incretin mimetics, including albiglutide, dulaglutide and semaglutide, are designed to have extended pharmacokinetic profiles and efficacy suitable once-weekly administration
There is nothing more frustrating than going through the full intake process only to find out that you can expect to pay $499 just a couple of months into treatment
Kandace McGuire, chief of breast surgery at the Massey Comprehensive Cancer Center at Virginia Commonwealth University, said that might explain the counterintuitive nature of the findings
The Academy of Nutrition and Dietetics offers a Find a Nutrition Expert database that can connect you with a qualified nutrition professional
GLP-1s cannot replace fertility treatments
Its my hope that this blog will offer some clarity and needed nuance around GLP-1s from a weight-neutral lens